Go offline with the Player FM app!
Dr. Marc Hedrick, MD - CEO, Plus Therapeutics - Radiotherapeutics For Difficult-To-Treat CNS Cancers
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on December 02, 2025 22:35 ()
What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 522337651 series 2835025
Dr. Marc Hedrick, MD is President and CEO of Plus Therapeutics, Inc. ( https://plustherapeutics.com/ ), a U.S. clinical-stage pharmaceutical company, focused on developing innovative, targeted radiotherapeutics for adults and children with difficult-to-treat cancers of the central nervous system. The company’s lead programs focus on leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), leveraging image-guided local beta radiation and targeted drug delivery to improve outcomes.
Additionally, Plus' subsidiary CNSide Diagnostics develops proprietary lab tests such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases.
Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.
Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).
Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
#MarcHedrick #PlusTherapeutics #Radiotherapeutics #Cancer #CentralNervousSystem #Glioblastoma #LeptomeningealMetastases #Rhenium #ConvectionEnhancedDelivery #Oncology #Theranostic #NanoliposomeTechnology #Radioembolization #AlginateMicrospheres#BMEDAChelation#CNSide #REYOBIQ #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
728 episodes
Dr. Marc Hedrick, MD - CEO, Plus Therapeutics - Radiotherapeutics For Difficult-To-Treat CNS Cancers
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on December 02, 2025 22:35 ()
What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 522337651 series 2835025
Dr. Marc Hedrick, MD is President and CEO of Plus Therapeutics, Inc. ( https://plustherapeutics.com/ ), a U.S. clinical-stage pharmaceutical company, focused on developing innovative, targeted radiotherapeutics for adults and children with difficult-to-treat cancers of the central nervous system. The company’s lead programs focus on leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), leveraging image-guided local beta radiation and targeted drug delivery to improve outcomes.
Additionally, Plus' subsidiary CNSide Diagnostics develops proprietary lab tests such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases.
Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.
Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).
Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
#MarcHedrick #PlusTherapeutics #Radiotherapeutics #Cancer #CentralNervousSystem #Glioblastoma #LeptomeningealMetastases #Rhenium #ConvectionEnhancedDelivery #Oncology #Theranostic #NanoliposomeTechnology #Radioembolization #AlginateMicrospheres#BMEDAChelation#CNSide #REYOBIQ #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
728 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.